Mark J Cantwell

USPTO Granted Patents = 13 (Patent Applications = 5)

CIPO Patents = 1 (Patent Applications = 6)

EPO Patents = 3 (Patent Applications = 8)

Average Co-Inventor Count = 2.6

ph-index = 4

Forward Citations = 82(Granted Patents)

Location History:

La Jolla, CA (US) (2006 - 2011)
San Diego, CA (US) (2009 - 2023)
Meadow Vista, CA (US) (2024)

Company Filing History:

8 out of 15,475

University of California

H. Lee Moffitt Cancer Center and Research Institute, Inc.

patents

4. 2 out of 5,450

The University of Texas System

patents

where one patent can have more than one assignee

Years Active: 2006-2025

Loading Chart...

13 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12239666 - Oncolytic virus or antigen presenting cell mediated cancer therapy using type I interferon and CD40-ligand (2025-03-04),

2. 12171803 - Methods of CD40 and toll like receptor immune activation (2024-12-24),

3. 11951141 - Replication-enhanced oncolytic adenoviruses (2024-04-09),

4. 11594135 - Methods of CD40 activation and immune checkpoint blockade (2023-02-28),

5. 11298420 - Armed oncolytic viruses (2022-04-12),

6. 8138310 - Chimeric CD154 polypeptides (2012-03-20),

7. 7964712 - Chimeric nucleic acids encoding polypeptides comprising TNF alpha, CD70 and FAS ligand domains (2011-06-21),

8. 7928213 - Nucleic acids encoding chimeric CD154 polypeptides (2011-04-19),

9. 7906638 - Chimeric nucleic acids encoding polypeptides comprising CD70 and Fas ligand domains (2011-03-15),

10. 7786282 - Nucleic acid molecules encoding TNF-α ligand polypeptides having a CD154 domain (2010-08-31),

11. 7524944 - Chimeric nucleic acids encoding polypeptides comprising CD154 and TNF-α (2009-04-28),

12. 7495090 - Nucleic acids encoding chimeric CD154 polypeptides (2009-02-24),

13. 7070771 - Methods of expressing chimeric mouse and human CD40 ligand in human CD40+ cells (2006-07-04),

Title: Inventor Mark J. Cantwell: Pioneering Cancer Therapies

Introduction

Mark J. Cantwell is a distinguished inventor based in San Diego, California, renowned for his contributions to cancer treatment through innovative therapeutic techniques. With an impressive portfolio of 13 patents, he has dedicated much of his career to developing groundbreaking methods for combating malignancies, primarily focusing on immunotherapy.

Latest Patents

Among Mark J. Cantwell's notable inventions are two recent patents that showcase his expertise in cancer therapy. The first patent explores an oncolytic virus or antigen-presenting cell (APC) mediated cancer therapy using type I interferon and CD40-ligand. This invention details the use of APCs, such as dendritic cells, that integrate a combination of exogenous type I interferon and CD40-ligand to treat malignancies effectively. The methods involve administering these modified APCs to patients, and in some cases, utilizing irradiation therapy beforehand.

The second patent focuses on methods of immune activation involving CD40 and toll-like receptors. This patent outlines protocols for treating cancer by administering an effective amount of a toll-like receptor agonist along with a chimeric CD154 polypeptide, which enhances immune function in patients.

Career Highlights

Throughout his career, Mark has made significant strides in cancer research and therapy methodologies. He has been associated with prestigious institutions like the University of California, where his work has received recognition for its innovative approach to treatment. Additionally, his time at Memgen, Inc. has further solidified his reputation as a leader in the field of cancer immunotherapy.

Collaborations

Collaboration has been a cornerstone of Mark J. Cantwell’s career. He has worked alongside notable colleagues such as Thomas James Kipps and Charles E. Prussak, with whom he has co-developed various patent portfolios that push the boundaries of cancer treatment and research.

Conclusion

Mark J. Cantwell continues to be a driving force in cancer research with an extensive array of patents that not only enhance therapeutic modalities but also pave the way for future innovations in oncology. His commitment to developing effective cancer treatments combines scientific rigor with a genuine desire to improve patient outcomes.

This text is generated by artificial intelligence and may not be accurate.